Literature DB >> 23698299

Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin.

Peter H Goff1, Florian Krammer, Rong Hai, Christopher W Seibert, Irina Margine, Adolfo García-Sastre, Peter Palese.   

Abstract

Severe human disease caused by the emerging H7N9 influenza virus in China warrants a rapid response. Here, we present a recombinant Newcastle disease virus expressing a North American lineage H7 influenza virus hemagglutinin. Sera from immunized mice were cross-reactive to a broad range of H7 subtype viruses and inhibited hemagglutination by the novel H7 hemagglutinin. Immunized mice were protected against a heterologous H7 subtype challenge, and genetic analysis suggested that cross-protective antibodies recognize conserved antigenic sites.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23698299      PMCID: PMC3700175          DOI: 10.1128/JVI.01085-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  A proof-of-principle study to identify suitable vaccine seed candidates to combat introductions of Eurasian lineage H5 and H7 subtype avian influenza viruses.

Authors:  Maria Serena Beato; Isabella Monne; Marzia Mancin; Elena Bertoli; Ilaria Capua
Journal:  Avian Pathol       Date:  2010-10       Impact factor: 3.378

2.  Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada.

Authors:  Danuta M Skowronski; Yan Li; S Aleina Tweed; Theresa W S Tam; Martin Petric; Samara T David; Fawziah Marra; Nathalie Bastien; Sandra W Lee; Mel Krajden; Robert C Brunham
Journal:  CMAJ       Date:  2007-01-02       Impact factor: 8.262

3.  Use of vaccination in avian influenza control and eradication.

Authors:  S Marangon; M Cecchinato; I Capua
Journal:  Zoonoses Public Health       Date:  2008       Impact factor: 2.702

Review 4.  Development and application of avian influenza vaccines in China.

Authors:  Hualan Chen; Zhigao Bu
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

5.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

Authors:  Ron A M Fouchier; Peter M Schneeberger; Frans W Rozendaal; Jan M Broekman; Stiena A G Kemink; Vincent Munster; Thijs Kuiken; Guus F Rimmelzwaan; Martin Schutten; Gerard J J Van Doornum; Guus Koch; Arnold Bosman; Marion Koopmans; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

6.  A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.

Authors:  Rebecca J Cox; Abdullah S Madhun; Solveig Hauge; Haakon Sjursen; Diane Major; Mirjam Kuhne; Katja Höschler; Melanie Saville; Frederick R Vogel; Wendy Barclay; Isabella Donatelli; Maria Zambon; John Wood; Lars R Haaheim
Journal:  Vaccine       Date:  2009-02-02       Impact factor: 3.641

7.  Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model.

Authors:  Tomy Joseph; Josephine McAuliffe; Bin Lu; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

8.  A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.

Authors:  Kawsar R Talaat; Ruth A Karron; Karen A Callahan; Catherine J Luke; Susan C DiLorenzo; Grace L Chen; Elaine W Lamirande; Hong Jin; Kathy L Coelingh; Brian R Murphy; George Kemble; Kanta Subbarao
Journal:  Vaccine       Date:  2009-04-17       Impact factor: 3.641

9.  Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.

Authors:  Marion Koopmans; Berry Wilbrink; Marina Conyn; Gerard Natrop; Hans van der Nat; Harry Vennema; Adam Meijer; Jim van Steenbergen; Ron Fouchier; Albert Osterhaus; Arnold Bosman
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

10.  Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.

Authors:  Alison Whiteley; Diane Major; Isabelle Legastelois; Laura Campitelli; Isabella Donatelli; Catherine I Thompson; Maria C Zambon; John M Wood; Wendy S Barclay
Journal:  Influenza Other Respir Viruses       Date:  2007-07       Impact factor: 4.380

View more
  34 in total

1.  Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase.

Authors:  Cassandra L Pegg; Christine Hoogland; Jeffrey J Gorman
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

2.  Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses.

Authors:  Qinfang Liu; Ignacio Mena; Jingjiao Ma; Bhupinder Bawa; Florian Krammer; Young S Lyoo; Yuekun Lang; Igor Morozov; Gusti Ngurah Mahardika; Wenjun Ma; Adolfo García-Sastre; Juergen A Richt
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

3.  H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids.

Authors:  Irene Ramos; Florian Krammer; Rong Hai; Domingo Aguilera; Dabeiba Bernal-Rubio; John Steel; Adolfo García-Sastre; Ana Fernandez-Sesma
Journal:  J Gen Virol       Date:  2013-08-15       Impact factor: 3.891

4.  Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain.

Authors:  Dirk Eggink; Peter H Goff; Peter Palese
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

5.  Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.

Authors:  Zhongying Chen; Mariana Baz; Janine Lu; Myeisha Paskel; Celia Santos; Kanta Subbarao; Hong Jin; Yumiko Matsuoka
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

Review 6.  Mammalian models for the study of H7 virus pathogenesis and transmission.

Authors:  Jessica A Belser; Terrence M Tumpey
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

7.  A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.

Authors:  Joost H C M Kreijtz; Lidewij C M Wiersma; Heidi L M De Gruyter; Stella E Vogelzang-van Trierum; Geert van Amerongen; Koert J Stittelaar; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

8.  An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Authors:  Florian Krammer; Asne Jul-Larsen; Irina Margine; Ariana Hirsh; Haakon Sjursen; Maria Zambon; Rebecca J Cox
Journal:  Clin Vaccine Immunol       Date:  2014-06-18

9.  Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.

Authors:  Xiaohui Li; Peter Pushko; Irina Tretyakova
Journal:  J Vaccines Vaccin       Date:  2015-06-30

10.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.

Authors:  Irina Margine; Peter Palese; Florian Krammer
Journal:  J Vis Exp       Date:  2013-11-06       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.